Morehouse School of Medicine.
Division of Nuclear Medicine and Molecular Imaging, Department of Radiology and Imaging Sciences.
Nucl Med Commun. 2021 Aug 1;42(8):892-898. doi: 10.1097/MNM.0000000000001420.
To evaluate the relationship between Yttrium-90 (Y90) tumour dose and response rate in patients with hepatocellular carcinoma (HCC) who undergo Y90 radiation segmentectomy (Y90-RS) and to determine implication on overall survival (OS).
Post Y90-RS Bremsstrahlung single-photon emission computed tomography/CT of 105 HCC patients with 110 treatments performed with glass microspheres was retrospectively analysed. The dose-volume histogram of the targeted tumour was determined with commercially available dosimetry software. Tumour response at 3 months was evaluated using modified Response Evaluation Criteria in Solid Tumours. Tumour dose thresholds associated with the objective response with 80% specificity were then used to evaluate implication on OS using Kaplan-Meier estimation and log-rank analysis.
Tumour dose thresholds to predict objective response with 80% specificity were the following: maximum tumour dose (748 Gy), mean tumour dose (568 Gy), minimum tumour dose of 30% tumour volume (608 Gy), minimum tumour dose of 50% tumour volume (565 Gy), minimum tumour dose of 70% tumour volume (464 Gy) and minimum tumour dose of 100% tumour volume (213 Gy). These parameters all significantly predicted tumour response with areas under the ROC curve of >0.6. Mean tumour dose of ≥250 Gy predicted median OS of 43.67 vs. 17.87 months for others (P = 0.026). Minimum dose ≥180 Gy to 100% of tumour volume predicted median OS of 44.93 vs. 35.87 months for others (P = 0.043).
In patients with HCC undergoing Y90-RS, mean tumour dose ≥250 Gy and minimum tumour dose of ≥180 Gy to 100% of tumour volume are both significantly correlated with higher objective tumour response and prolonged survival.
评估接受钇-90(Y90)放射性切除术(Y90-RS)的肝细胞癌(HCC)患者的 Y90 肿瘤剂量与反应率之间的关系,并确定其对总生存期(OS)的影响。
回顾性分析了 105 例 HCC 患者的 110 次 Y90-RS 布雷斯特拉hlung 单光子发射计算机断层扫描/CT 检查,这些患者均采用玻璃微球进行治疗。使用商业可得的剂量测定软件确定目标肿瘤的剂量体积直方图。采用改良的实体瘤反应评价标准(mRECIST)在 3 个月时评估肿瘤反应。然后,使用 Kaplan-Meier 估计和对数秩分析,使用预测客观反应的 80%特异性的肿瘤剂量阈值来评估对 OS 的影响。
预测客观反应的肿瘤剂量阈值为 80%特异性,包括最大肿瘤剂量(748 Gy)、平均肿瘤剂量(568 Gy)、30%肿瘤体积最小肿瘤剂量(608 Gy)、50%肿瘤体积最小肿瘤剂量(565 Gy)、70%肿瘤体积最小肿瘤剂量(464 Gy)和 100%肿瘤体积最小肿瘤剂量(213 Gy)。这些参数的 ROC 曲线下面积均>0.6,均能显著预测肿瘤反应。平均肿瘤剂量≥250 Gy 预测中位 OS 为 43.67 个月,而其他患者为 17.87 个月(P=0.026)。最小肿瘤剂量≥180 Gy 至 100%肿瘤体积预测中位 OS 为 44.93 个月,而其他患者为 35.87 个月(P=0.043)。
在接受 Y90-RS 的 HCC 患者中,平均肿瘤剂量≥250 Gy 和最小肿瘤剂量≥180 Gy 至 100%肿瘤体积与更高的客观肿瘤反应和延长的生存时间均显著相关。